PPIDT00194
Drug Information
| Name | Tocilizumab |
|---|---|
| Sequence | DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
| DrugBank_ID | DB06273 |
| Type | biotech |
| Indication | Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.[L12789, L43697, L48385] Tocilizumab is also used to treat coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).[L40169,L43697,L44483] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Intravenous |
162 mg/0.9ml
|
| Injection | Intravenous |
20 MG/ML
|
| Injection, solution, concentrate | Intravenous |
20 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
400 mg/20mL
|
| Injection, solution, concentrate | Intravenous |
80 mg/4mL
|
| Solution | Intravenous |
200 mg / 10 mL
|
| Solution | Intravenous |
400 mg / 20 mL
|
| Solution | Intravenous |
80 mg / 4 mL
|
| Solution | Subcutaneous |
162 mg / 0.9 mL
|
| Injection, solution | — |
162 mg/0.9mL
|
| Injection, solution | Subcutaneous |
162 mg/0.9mL
|
| Injection, solution | Intravenous |
|
| Solution | Intravenous |
20 mg/ml
|
| Solution | Intravenous |
80 mg
|
| Solution | Intravenous |
200 mg
|
| Solution | Intravenous |
20000000 mg
|
| Solution | Intravenous |
40000000 mg
|
| Solution | Intravenous |
8000000 mg
|
| Solution | Subcutaneous |
162 mg
|
| Solution | Subcutaneous |
16200000 mg
|
| Injection, solution | Parenteral; Subcutaneous |
162 MG
|
| Injection, solution, concentrate | Intravenous |
20 MG/ML
|
| Solution | Intravenous |
80.000 mg
|
| Solution | Subcutaneous |
162.000 mg
|
| Injection | Intravenous |
20 mg/1mL
|
| Injection, solution | Subcutaneous |
162 mg
|
| Injection, solution, concentrate | Intravenous |
200 mg/10mL
|